R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.
hERG1a (D1Y2J) Rabbit mAb #12889
Filter:
- WB
Supporting Data
| REACTIVITY | H R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 135, 155 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
hERG1a (D1Y2J) Rabbit mAb recognizes endogenous levels of both mature and immature hERG1a protein. This antibody cross-reacts with proteins of unknown origin at 65 and 42 kDa in some cell lines. This antibody does not recognize hERG1b protein.
Species Reactivity:
Human, Rat
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala223 of human hERG1a protein.
Background
hERG1(human ether-a-go-go-related gene potassium channel 1) is a voltage gated potassium channel alpha-subunit which mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr) (1,2). The hERG channel is composed of two subunits, 1a and 1b, which differ at amino terminus due to alternative splicing. Native hERG channels are heteromers of hERG1a with hERG1b. Both subunits contribute to IKr current (3-6).
Blockade of hERG currents induced by compounds or mutation of hERG encoding gene-KCNH2 causes ventricular arrhythmias associated with inherited and acquired long QT syndrome and cardiomyocyte apoptosis (7-10). Therefore, hERG channel is a primary target for the development of class III antiarrhythmic agents (11,12). The hERG channel is also inhibited by a variety of non-antiarrhythmic compounds, which result in side effects. Consequently, hERG channel blockage is a common counter screen when selecting therapeutic agents for various diseases (11,13,14).
Research studies have implicated hERG in cancer cell survival (15). In normal human adult tissue, hERG is expressed in heart, brain, myometrium, pancreas, and hematopoietic progenitors (16,17). hERG is expressed in various cancer cell lines of epithelial, neuronal, leukemic, and connective tissue origin but not in corresponding normal cells (18-22). Furthermore, hERG expression is associated with enhanced cancer cell proliferation, invasiveness, and poor prognosis (23,24).
Blockade of hERG currents induced by compounds or mutation of hERG encoding gene-KCNH2 causes ventricular arrhythmias associated with inherited and acquired long QT syndrome and cardiomyocyte apoptosis (7-10). Therefore, hERG channel is a primary target for the development of class III antiarrhythmic agents (11,12). The hERG channel is also inhibited by a variety of non-antiarrhythmic compounds, which result in side effects. Consequently, hERG channel blockage is a common counter screen when selecting therapeutic agents for various diseases (11,13,14).
Research studies have implicated hERG in cancer cell survival (15). In normal human adult tissue, hERG is expressed in heart, brain, myometrium, pancreas, and hematopoietic progenitors (16,17). hERG is expressed in various cancer cell lines of epithelial, neuronal, leukemic, and connective tissue origin but not in corresponding normal cells (18-22). Furthermore, hERG expression is associated with enhanced cancer cell proliferation, invasiveness, and poor prognosis (23,24).
- Warmke, J.W. and Ganetzky, B. (1994) Proc Natl Acad Sci U S A 91, 3438-42.
- Sanguinetti, M.C. and Tristani-Firouzi, M. (2006) Nature 440, 463-9.
- Lees-Miller, J.P. et al. (1997) Circ Res 81, 719-26.
- London, B. et al. (1997) Circ Res 81, 870-8.
- Lees-Miller, J.P. et al. (2003) Mol Cell Biol 23, 1856-62.
- Sale, H. et al. (2008) Circ Res 103, e81-95.
- Curran, M.E. et al. (1995) Cell 80, 795-803.
- Itoh, T. et al. (1998) Hum Genet 102, 435-9.
- González-Juanatey, J.R. et al. (2003) Circulation 107, 127-31.
- Gong, Q. et al. (2006) J Biol Chem 281, 4069-74.
- Thomas, D. et al. (2006) Curr Pharm Des 12, 2271-83.
- Staudacher, I. et al. (2010) Curr Opin Drug Discov Devel 13, 23-30.
- Wible, B.A. et al. (2005) J Pharmacol Toxicol Methods 52, 136-45.
- Yang, B.F. et al. (2004) Acta Pharmacol Sin 25, 554-60.
- Jehle, J. et al. (2011) Cell Death Dis 2, e193.
- Pond, A.L. et al. (2000) J Biol Chem 275, 5997-6006.
- Rosati, B. et al. (2000) FASEB J 14, 2601-10.
- Smith, G.A. et al. (2002) J Biol Chem 277, 18528-34.
- Lastraioli, E. et al. (2004) Cancer Res 64, 606-11.
- Masi, A. et al. (2005) Br J Cancer 93, 781-92.
- Lin, H. et al. (2007) J Cell Physiol 212, 137-47.
- Gong, J.H. et al. (2010) Oncol Rep 23, 1747-56.
- Ding, X.W. et al. (2008) J Surg Oncol 97, 57-62.
- Shao, X.D. et al. (2008) Cancer Biol Ther 7, 45-50.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意，否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件，除非书 CST 的合法授书代表以书面形式书独接受， 否书均被拒书，并且无效。
专品专有“专供研究使用”的专专或专似的专专声明， 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的， 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专，且专用于研专用途。将专品用于专断、专防或治专目的， 或专专售（专独或作专专成）或其他商专目的而专专专品，均需要 CST 的专独专可。客专：(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品，或使用专品制造任何商专专品，(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专，或使用专品开专任何与 CST 的专品或服专专争的专品或服专， (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专，(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品， (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.